-- 根據FactSet調查的分析師報告，Generate Biomedicines (GENB) 的平均評級為“買入”，平均目標價為25美元。 （報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）
Related Articles
Asia
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.
$ASX:XRF
Asia
Sprintex Raising AU$1.1 Million Via Convertible Notes Issue
Sprintex (ASX:SIX) is raising about AU$1.1 million through the issue of nearly 1.1 million convertible notes at a price of AU$1 each, according to a Monday filing with the Australian bourse.The notes will mature on June 30, 2027, and bear interest at 8% per year, per the filing.Holders of the notes can convert them into Sprintex ordinary shares at any time after June 30 and before their maturity.The company said it plans to use the funds for general working capital purposes, to expand its sales team, and to fulfill customer orders.
$ASX:SIX
Asia
Immutep Says Bank of New York Mellon Increases Stake
Immutep (ASX:IMM) received notice that Bank of New York Mellon and its affiliated entities increased their holdings in the company to 21.11% from 20.08%, according to a Monday filing with the Australian bourse.Bank of New York Mellon and its affiliates now owns over 311 million shares in the company, the filing said.
$ASX:IMM